论文部分内容阅读
目的探讨三维适形放疗联合同步化疗在食管癌治疗中的临床应用价值。方法选取2010年5月—2012年5月诊治的食管癌患者144例,随机分为对照组和观察组各72例,对照组行三维适形放疗,观察组行三维适形放疗联合同步化疗,比较两组近期疗效、不良反应、生活质量、1年生存率。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果总有效率对照组68.06%,观察组90.28%,两组比较差异有统计学意义(χ2=10.779,P<0.05)。患者行为状态改善率、体重变化率对照组分别为44.44%、13.89%,观察组分别为62.50%、33.33%,两组比较差异均有统计学意义(χ2=4.717、7.547,均P<0.05);观察组1年生存率(76.39%)明显高于对照组(45.83%),两组比较差异有统计学意义(χ2=14.143,P<0.05)。结论三维适形放疗联合同步化疗能够有效提高食管癌近期治疗效果,缓解放化疗不良反应,提高生存率。
Objective To investigate the clinical value of three-dimensional conformal radiotherapy combined with concurrent chemotherapy in the treatment of esophageal cancer. Methods A total of 144 patients with esophageal cancer diagnosed and treated from May 2010 to May 2012 were randomly divided into control group and observation group with 72 cases in each group. The control group received three-dimensional conformal radiotherapy, the observation group received three-dimensional conformal radiotherapy combined with concurrent chemotherapy, The two groups were compared the short-term efficacy, adverse reactions, quality of life, 1-year survival rate. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate was 68.06% in the control group and 90.28% in the observation group. There was significant difference between the two groups (χ2 = 10.779, P <0.05). The rate of improvement of behavioral status and body weight were 44.44% and 13.89% in the control group and 62.50% and 33.33% in the observation group respectively (χ2 = 4.717 and 7.547, both P <0.05) . The 1-year survival rate (76.39%) in the observation group was significantly higher than that in the control group (45.83%). There was significant difference between the two groups (χ2 = 14.143, P <0.05). Conclusion Three-dimensional conformal radiotherapy combined with concurrent chemotherapy can effectively improve the short-term treatment effect of esophageal cancer, relieve the adverse reactions of radiotherapy and chemotherapy, and improve the survival rate.